Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer

Targeted drug decisions in metastatic renal cell carcinoma are exclusively made on the basis of clinical criteria. We investigated whether these biomarkers (HIF-1α, HIF-2α, CAIX, VEGF, VEGFR1, VEGFR2, VEGFR3, PDGFB, PDGFRA, PDGFRB, CD31, CD44, bcl-xL, KIT, p21, CXCR4, PTEN, (CSF)-1R, RET, and FLT-3)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xin, Wang, Lei, Li, Hongzhao, Zhang, Yu, Gao, Yu, Guo, Gang, Liu, Kan, Meng, Qingyu, Zhao, Chaofei, Wang, Dianjun, Song, Zhigang, Zhang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973254/
https://www.ncbi.nlm.nih.gov/pubmed/27488093
http://dx.doi.org/10.1038/srep30886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973254/
https://www.ncbi.nlm.nih.gov/pubmed/27488093
http://dx.doi.org/10.1038/srep30886

Ejemplares similares